Načítá se...
Current development of chimeric antigen receptor T-cell therapy
Chimeric antigen receptor (CAR) T-cell therapy has achieved great success in recent years, with encouraging complete remission rate and long-term durability of response, especially in advanced B-cell malignancies. With the approval of tisagenlecleucel and axi-cel by FDA to treat refractory/relapsed...
Uloženo v:
| Vydáno v: | Stem Cell Investig |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AME Publishing Company
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6327156/ https://ncbi.nlm.nih.gov/pubmed/30701179 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/sci.2018.11.05 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|